<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="tbl1" position="float">
 <label>Table I</label>
 <caption>
  <p>Profile of ongoing and anticipated candidate Ebola vaccines trial</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Vaccine type</th>
    <th>Manufacturers</th>
    <th>Vaccination approach/target</th>
    <th>Progress (including success in animal studies)</th>
    <th>Future plans</th>
    <th>Issues and concerns</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td colspan="6">Current trials on candidate Ebola vaccines</td>
   </tr>
   <tr>
    <td> ChAd3-ZEBOV: Chimpanzee adenovirus serotype 3 encoding the monovalent Zaire strain of EV glycoprotein</td>
    <td>GlaxoSmithKline, Research Triangle Park, NC; National Institutes of Health, Bethesda, Md</td>
    <td>Pre-exposure for frontline health workers</td>
    <td>Phase I trials are nearing completion in the United Kingdom and Mali.</td>
    <td>Parallel phase II/III trials are planned to start in Liberia or Sierra Leone in early 2015.</td>
    <td>ChAd3 are genetically modified vectors with biosafety level 2 status. The vaccine is administered intravenously and requires storage at −80°C.</td>
   </tr>
   <tr>
    <td> ChAd3-EBO: Chimpanzee adenovirus serotype 3 encoding bivalent Sudan and Zaire EV glycoproteins</td>
    <td>GlaxoSmithKline, National Institutes of Health</td>
    <td>Pre-exposure for frontline health workers</td>
    <td>Preliminary findings of phase I trial in the United States showed promising safety and immunogenic profiles.
     <xref rid="bib62" ref-type="bibr">
      <sup>62</sup>
     </xref>
    </td>
    <td>Expanded phase I/Ib trials for dose selection, efficacy evaluation, and MVA-EBO booster regimen are planned for 2015.</td>
    <td>Current epidemic in West Africa is caused by the Zaire strain, limiting possible deployment in the event of proved efficacy.</td>
   </tr>
   <tr>
    <td> rVSV-EBOV: Attenuated version of recombinant vesicular stomatitis virus expressing EV glycoprotein</td>
    <td>NewLink Genetics, Ames, Iowa (Public Health Agency of Canada's National Microbiology Laboratory [NML]).</td>
    <td>Postexposure</td>
    <td>Has demonstrated efficacy in rodents and nonhuman primates; however, it currently trails behind ChAd3-ZEBOV in phase I trials. Report of arthralgia among volunteers in a Swiss trial led to a temporary halt.</td>
    <td>Concurrent efficacy trials along with ChAd3-ZEBOV in worst-hit countries</td>
    <td>Efficacy is likely to depend on filovirus species and early commencement of intervention after exposure.</td>
   </tr>
   <tr>
    <td colspan="6">Anticipated Ebola vaccine trials</td>
   </tr>
   <tr>
    <td> Ad 25, Ad 35, MVA candidates: Heterologous prime-boost approach using human adenoviruses 25 and 35 and MVA vectors</td>
    <td>Johnson &amp; Johnson, New Brunswick, NJ; Bavarian Nordic, Kvistgaard, Denmark</td>
    <td>Pre-exposure</td>
    <td>Has shown demonstrated efficacy in rodents and nonhuman primates. Phase I trials are planned for early 2015.</td>
    <td>Will depend on phase I data</td>
    <td>High pre-existing antibody against human adenovirus vectors</td>
   </tr>
   <tr>
    <td> Recombinant protein–Ebola glycoprotein</td>
    <td>Protein Sciences</td>
    <td>Pre-exposure</td>
    <td>Has demonstrated efficacy in rodents. Human trials are scheduled in 2015.</td>
    <td>Will depend on phase I data</td>
    <td>Limited safety data in human subjects</td>
   </tr>
   <tr>
    <td> EBOV GP Vaccine: Recombinant nanoparticle using adjuvant Matrix-M: first Ebola vaccine candidate based on the 2014 Guinea Ebola strain genetic sequence</td>
    <td>Novavax, Gaithersburg, Md</td>
    <td>Pre-exposure</td>
    <td>Robust immune responses demonstrated in preclinical studies; exceptional responses were seen when used with Novavax Matrix-M adjuvant.
     <break/>Nonhuman primate study was initiated. GMP manufacture was initiated. Scaled-up manufacturing is to begin in first quarter of 2015. Phase 1 clinical trial is anticipated to start in December 2014.
    </td>
    <td>Will depend on phase I data</td>
    <td>Limited safety data on Matrix-M adjuvant in human subjects</td>
   </tr>
   <tr>
    <td> Oral Ad5: Oral tablet vaccine based on human adenovirus</td>
    <td>Vaxart, South San Francisco, Calif</td>
    <td>Pre-exposure</td>
    <td>Protective against challenge in preclinical studies; clinical trials are anticipated in early 2015.</td>
    <td>Will depend on phase I data</td>
    <td>High pre-existing antibody against human adenovirus vectors</td>
   </tr>
   <tr>
    <td> rVSV-EBOV: Another vesicular stomatitis vector based vaccine</td>
    <td>Profectus Biosciences, Baltimore, Md</td>
    <td>Pre-exposure</td>
    <td>Safety data are available in this vaccine component expressing HIV gag. Phase I trials are planned for second quarter of 2015.</td>
    <td>Will depend on phase I data</td>
    <td>Safety issue as vaccine is replication competent</td>
   </tr>
   <tr>
    <td> DNA-EBOV: Multiagent filovirus DNA vaccine delivered by means of intramuscular electroporation</td>
    <td>Inovio, San Diego, Calif</td>
    <td>Pre-exposure and postexposure</td>
    <td>Phase I trials in 2015</td>
    <td>Will depend on phase I data</td>
    <td>Limited safety data and delivery challenges</td>
   </tr>
   <tr>
    <td> Recombinant rabies EBOV: (chemically inactivated [killed] rabies virus virions containing EBOV glycoprotein)</td>
    <td>National Institutes of Health</td>
    <td>Pre-exposure and postexposure</td>
    <td>Excellent protection in mice against lethal challenge with the mouse adapted EBOV and RABV; phase I trials will occur in 2015.</td>
    <td>Will depend on phase I data</td>
    <td>No safety data in human subjects</td>
   </tr>
   <tr>
    <td> Three potential vaccines: Triazoverin based on an EV strain and the other 2 based on recombinant mAbs</td>
    <td>Russian Ministry of Health, Moscow, Russia</td>
    <td>Preventive and therapeutic</td>
    <td>Efficiency is said to range between 70% and 90%. There are plans to send the vaccines to affected West African countries by December 2014.</td>
    <td>Will depend on phase I data</td>
    <td>No safety data in human subjects</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
